The companies will work together to support the development of additional clinical validation, to generate real-world evidence, and to support the adoption of noninvasive diagnostic tests for the disease. They will also collaborate on communicating the importance of early diagnosis and management.

Echosens and Novo Nordisk said they have a shared goal of doubling diagnostic rates for people living with advanced to severe steatohepatitis by 2025.